Skip to main content
Psych Congress  

Impact of Individual and Class of Concomitant Oral Antidepressant on the Efficacy and Safety of Esketamine Nasal Spray in Patients With Treatment Resistant Depression

Authors  

Muideen Adigun, Pharm.D. – Janssen Scientific Affairs, LLC, Titusville, NJ; Jennifer Kern-Sliwa, PharmD, BCPP – Janssen Scientific Affairs, LLC, Titusville, NJ; Ibrahim Turkoz, PhD – Janssen Research & Development, LLC, Titusville, NJ; Stephane Borentain, MD – Janssen Scientific Affairs, LLC, Titusville, NJ; Jaskaran Singh, MD – Janssen Research & Development, LLC, Titusville, NJ; Ella Daly, MD, BCh, BAO, MRC Pysch – Janssen Scientific Affairs, LLC, Titusville, NJ

Sponsor  
Janssen Scientific Affairs, LLC

Objective: Phase 3 trials have demonstrated the efficacy and safety of esketamine nasal spray (ESK) plus a newly initiated oral antidepressant (AD) for treatment-resistant depression (TRD). This analysis examined the impact of individual ADs (duloxetine, escitalopram, sertraline, venlafaxine XR) or AD class (selective serotonin reuptake inhibitors [SSRIs] or serotonin and norepinephrine reuptake inhibitors [SNRIs]) on outcomes.

Methods: This post hoc analysis of pooled data from two phase 3 ESK trials (TRANSFORM-1, NCT02417064; TRANSFORM-2, NCT02418585) assessed mean change from baseline to day 28 in Montgomery–Åsberg Depression Rating Scale (MADRS) total score, and proportion of patients exhibiting response and remission. Safety assessments included treatment-emergent adverse events. Efficacy and safety endpoints were analyzed by individual AD/AD class. Subgroup differences were examined using ANCOVA models or Cochran-Mantel-Haenzsel tests.

Results: Overall, 343 patients were included in the analyses. Mean change (SE) in MADRS total score at day 28 was -19.9 (0.8) with ESK+AD and was similar by individual AD/AD class. Overall, 58.7% and 42.2% of patients met criteria for response and remission, respectively. Response rates at day 28 were similar by individual ADs (duloxetine [n=138], 60.1%; escitalopram [n=63], 61.9%; sertraline [n=55], 49.0%, venlafaxine XR [n=54], 61.1%) and AD class (SSRI [n=118], 55.9%; SNRI [n=192], 60.4%). The overall rate of TEAEs was similar by concomitant individual AD/AD class.

Conclusion: Subgroup analyses from two phase 3 ESK trials in TRD showed no major differences in MADRS total score changes at day 28, response and remission rates, or rate of overall TEAEs by concomitant individual AD/AD class.

This poster was presented at the 32nd annual Psych Congress, held Oct. 3-6, 2019, in San Diego, California.

Back to Top